Regulatory approval

Published by the Health Service Executive. Approved

Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.

This is written in the approval document.

Reimbursement

Hospital

Citation

riTUXimab (S/C 1400mg) Maintenance Therapy-84 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6401/599_v2a_riTUXimab_SC_1400mg_Therapy_every_three_months.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD20 + Non-Hodgkin Lymphoma Rituximab
HSE (1) CD20 + Follicular Lymphoma Rituximab